SEC Form 4 · accession 0001144204-15-030332
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Klaus R Dr Veitinger
Director
Period of report
May 11, 2015
Accepted (ET)
May 13, 2015 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 11, 2015 | M | 391 | $21.50 | A | 2,557 | D | |
| Common Stock | May 11, 2015 | S | 158 | $272.79 | D | 2,399 | D | |
| Common StockF3 | May 11, 2015 | S | 233 | $283.3305 | D | 2,166 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF2 | $21.50 | May 11, 2015 | M | 391 | D | — | Nov 16, 2022 | Common Stock | 391 | 8,363 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 13, 2014.
- F2All shares underlying this option have vested.
- F3This transaction was executed in multiple trades at prices ranging from $283.2650 to $283.7200. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.